Eyob Makonnen
Endocrinology, Diabetes & Metabolism · Annapolis, MDNPI 1396904207
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $171,650 of the $204,818 with a category attached, or 83.8%. Lilly USA, LLC accounts for 76.0% of it on its own, with 43 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 708 payments — averaging $289.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$156K
- Abbott$42K
- Novo Nordisk$1K
- Amgen$694
- Sanofi-aventis U.S. LLC$599
- AstraZeneca$564
- plus $4K from 38 others
What the payments were for
- Consulting fees$6,6753%
- Speaking & faculty fees$171,65084%
- Travel & lodging$13,2826%
- Food & beverage$13,1406%
- Education$710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$111,890
- FREESTYLE LIBRE 3$27,933
- LYUMJEV$20,238
- FreeStyle Libre Pro$5,481
- FreeStyle Libre$4,529
- FreeStyle Libre 2$2,900
- PROCLAIM$127
- EVENITY$122
- Ozempic$100
How this compares
$204,818 in reported general payments places this provider in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 349 | $684,649 |
| JardianceEmpagliflozin | 212 | $291,884 |
| TrulicityDulaglutide | 120 | $232,728 |
| MounjaroTirzepatide | 104 | $215,894 |
| Tresiba Flextouch U-100Insulin Degludec | 175 | $150,101 |
| Tresiba Flextouch U-200Insulin Degludec | 48 | $85,753 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 36 | $81,784 |
| JanuviaSitagliptin Phosphate | 47 | $64,122 |
| FarxigaDapagliflozin Propanediol | 53 | $62,259 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 73 | $50,217 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 44 | $45,801 |
| Humalog Kwikpen U-100Insulin Lispro | 76 | $32,999 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 27 | $32,688 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $32,037 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 112 | $23,893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,221 | $712,614372 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $155,674 | $448,622224 claims |
| Boehringer IngelheimJardiance | $368 | $291,884212 claims |
| MerckJanuvia, Janumet | $66 | $77,87963 claims |
| AstraZenecaFarxiga | $564 | $62,25953 claims |
| AbbVieSynthroid | $161 | $11,365136 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $171 | $7,045602 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Annapolis
- Darshana PurohitAnnapolis$25K
- Barbara OnumahAnnapolis$12K
- Kavita IyengarAnnapolis$9K
- Jocelyn UriosteguiAnnapolis$7K
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.